Buy or sell CarbonCure Technologies stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

CarbonCure Technologies Stock
CarbonCure Technologies creates, develops, and licenses solutions that consume waste CO2 to make better concrete.
About CarbonCure Technologies Stock
CarbonCure Technologies creates, develops, and licenses solutions that consume waste CO2 to make better concrete. It spurs the market shift towards affordable green concrete, by enabling concrete manufacturers to convert waste CO2 into solid minerals, locked away as a solid within concrete during manufacturing. It is a green building technology company currently serving concrete product manufacturers in the US and Canada. It offers concrete producers the ability to manufacture green concrete products without compromising on either quality or price. CarbonCure is a retrofit innovation that repurposes CO2 gas from large final emitters as a feedstock in concrete plants. The gas is permanently converted into embedded solid mineral carbonates that yield material, environmental, and production advantages. By enabling concrete manufacturers to consume CO2 into concrete products during manufacturing, the technology differentiates an otherwise traditional commodity concrete product, while achieving superior material performance characteristics. In addition to technology, CarbonCure provides demand-pull marketing and environmental reporting/certification services to reinforce its customers’ exclusive competitive positioning. The technology is licensed at a very low-CAPEX to concrete producers, generating a recurring revenue stream. CarbonCure Technologies was founded in 2007 and is headquartered in Halifax, Nova Scotia.
Investors
BDC Venture Capital
Coveo, Hopper, ApplyBoard, Wattpad, Ranovus, CarbonCure Technologies, Rover
Breakthrough Energy Ventures
Nature's Fynd, QuantumScape, Pivot Bio, Turntide Technologies, Commonwealth Fusion, CarbonCure Technologies
Funding History
July 2011 | $1.1M |
---|---|
March 2012 | $3.5M |
November 2013 | $1.6M |
May 2015 | $3.0M |
May 2016 | $1.8M |
February 2020 | $2.0M |
Management
Chair Scientific Advisory
Kevin Cail
VP of Engineering
Dean Forgeron
VP of Technology Development
Sean Monkman
CEO / Founder
Robert Niven
Director of Sales
Don Gordon
VP of Marketing
Jennifer Wagner
VP of Material Science
Paul Sandberg
CEO, Director
Robert Niven
Board of Directors
Tony Bommel
Interim Chief Financial Officer
Keith Abriel
Chair of the Board
David Green
Board of Directors
Bill Holden
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase